Blood test guides Post-Surgery cancer treatment in new trial
NCT ID NCT06914011
First seen Jan 02, 2026 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tests whether using a blood test (ctDNA) to guide additional chemotherapy and an immunotherapy drug (tisleliizumab) after surgery can help prevent esophageal cancer from coming back. About 172 adults with locally advanced esophageal squamous cell carcinoma who had their tumor removed will be randomly assigned to either the guided treatment or standard follow-up. The goal is to see if the personalized approach improves how long people live without their cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.